KRAS and Patent ductus arteriosus: The slightly higher frequency of KRAS mutations in the study cohort may reflect that all of the patients had relapsed and refractory disease that was predominantly metastatic at the time of sequencing reflecting the adverse prognostic influence associated with KRAS mutation in PDA.